Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.
Intismeran autogene is jointly developed by Moderna Inc. (NASDAQ:MRNA) and Merck & Co. Inc. (NYSE:MRK).
• Tempus AI shares are experiencing downward pressure. Why are TEM shares declining?
Expanded Precision Oncology Alliances
The collaboration builds on joint efforts initiated last year and will support preparations for the potential commercialization of intismeran autogene.
As part of the collaboration, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS).
Subject to applicable regulatory approvals, Tempus will also provide NGS services to support the intismeran autogene design and manufacturing process.
Financial terms of the collaboration were not disclosed.
Enhancing Clinical Trial Design with Bristol Myers Squibb
In May, Tempus AI announced a new collaboration initiative with Bristol Myers Squibb Co. (NYSE:BMY) aimed at improving clinical trial design and increasing the Probability of Technical & Regulatory Success across five initial development programs.
The companies plan to use artificial intelligence, multimodal real-world data, and advanced data science tools to refine drug development strategies in oncology and neuroscience.
See More: Top Momentum Stocks
Strategic M&A and AI Infrastructure Expansion
In July, Tempus AI agreed to acquire Personalis, Inc. (NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities.
Tempus AI shares erased early losses and recovered after an initial sell off tied to the company’s acquisition of Personalis.
The acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in the MRD market. Tempus claims it presents a $20 billion opportunity.
Bristol Myers Squibb in July said it is significantly upgrading its computational capabilities by deploying an Nvidia DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems.
The strategic deployment establishes the most robust and energy-efficient single-owned artificial intelligence infrastructure currently operating within the life sciences sector.
TEM Price Action: Tempus AI shares were down 1.94% to $70.58 at the time of publication on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment